Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1262 | 56-12-2 |
| Dose | Unit | Route |
|---|---|---|
| 1 | g | O |
| 1 | g | P |
None
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -3.459 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.199 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.750 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 1.574 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 96.260 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 86.560 | % | High | 1 |
| herg | hERG pIC50 | 5.278 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.854 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 6.637 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 96.970 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPKAPK2,MTOR,NTRK1,NTRK2,PDK2,PDK4,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,ULK1,ZAP70 | 53 | |||
| kinase-selectivity-class | AXL,BRAF,CAMK2B,CAMK2D,CDK4,EIF2AK3,EPHB4,MAP2K6,MAPK7,MELK,PAK4,PRKCD,SIK2,STK33,SYK,TEK | 16 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 2.254 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 0.327 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 98.800 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.753 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 98.780 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 1.102 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 76.850 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 99.710 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 587.489 | uM | High | 1 |
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | N03AG03 | NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Fatty acid derivatives |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018682 | GABA Agents |
| CHEBI has role | CHEBI:25512 | neurotransmitter |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35623 | anticonvulsant |
| CHEBI has role | CHEBI:62488 | signalling molecule |
| CHEBI has role | CHEBI:75772 | <em>Saccharomyces cerevisiae </em> metabolite |
| CHEBI has role | CHEBI:77746 | human metabolite |
None
None
None
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.87 | acidic |
| pKa2 | 10.45 | Basic |
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium- and chloride-dependent GABA transporter 1 | Transporter | IC50 | 5.30 | CHEMBL | |||||
| Gamma-aminobutyric acid receptor subunit rho-1 | Ion channel | EC50 | 6.57 | CHEMBL | |||||
| Sodium- and chloride-dependent GABA transporter 3 | Transporter | IC50 | 5.15 | CHEMBL | |||||
| Sodium- and chloride-dependent betaine transporter | Transporter | IC50 | 4.44 | CHEMBL | |||||
| Platelet glycoprotein VI | Membrane receptor | Kd | 7.39 | CHEMBL | |||||
| Sodium- and chloride-dependent GABA transporter 2 | Transporter | IC50 | 4.58 | CHEMBL | |||||
| Sodium- and chloride-dependent GABA transporter 1 | Transporter | IC50 | 5.59 | CHEMBL | |||||
| Sodium- and chloride-dependent GABA transporter 1 | Transporter | IC50 | 5.14 | CHEMBL | |||||
| Gamma-aminobutyric acid receptor subunit alpha-1 | Ion channel | EC50 | 5 | CHEMBL | |||||
| Gamma-aminobutyric acid receptor subunit alpha-2 | Ion channel | IC50 | 7.66 | CHEMBL | |||||
| Sodium- and chloride-dependent GABA transporter 3 | Transporter | IC50 | 5.09 | CHEMBL | |||||
| Sodium- and chloride-dependent GABA transporter 2 | Transporter | IC50 | 5.30 | CHEMBL | |||||
| Sodium- and chloride-dependent GABA transporter 2 | Transporter | IC50 | 4.56 | CHEMBL | |||||
| Gamma-aminobutyric acid receptor subunit gamma-1 | Ion channel | IC50 | 7.48 | CHEMBL | |||||
| Gamma-aminobutyric acid type B receptor subunit 1 | GPCR | AGONIST | IC50 | 4.60 | IUPHAR |
| ID | Source |
|---|---|
| 4034308 | VUID |
| N0000191506 | NUI |
| 4034308 | VANDF |
| C0016904 | UMLSCUI |
| ABU | PDB_CHEM_ID |
| CHEMBL96 | ChEMBL_ID |
| D000613 | MESH_DESCRIPTOR_UI |
| 119 | PUBCHEM_CID |
| DB02530 | DRUGBANK_ID |
| 4617 | RXNORM |
| 006466 | NDDF |
| 259100002 | SNOMEDCT_US |
| CHEBI:16865 | CHEBI |
| 1067 | IUPHAR_LIGAND_ID |
| D005680 | MESH_DESCRIPTOR_UI |
| 2ACZ6IPC6I | UNII |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Gongjinhyang Qi and Jin Eye | HUMAN OTC DRUG LABEL | 1 | 53208-500 | CREAM | 0.02 mL | TOPICAL | unapproved drug other | 10 sections |